Skip to main content

Table 1 Characteristics of the patients at baseline

From: N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial

Characteristic Placebo (n = 40) NAC + DFX (n = 40)
Age, years, mean ± SD 56 ± 14 51 ± 16
Male sex, n (%) 23 (57) 20 (50)
Charlson comorbidity score, mean ± SD 2.4 ± 2.1 2.6 ± 2.3
Medical admission, n (%) 33 (82) 32 (80)
Sepsis at enrollment, n (%) 20 (50) 21 (52)
Cardiogenic shock, n (%) 10 (25) 9 (22)
Trauma, n (%) 6 (15) 7 (17)
APACHE II score, mean ± SD 19 ± 7 20 ± 7
SOFA score day 1, mean ± SD 9.4 ± 4 9.3 ± 3.7
Creatinine at enrollment, mean ± SD 1.0 ± 0.6 1.2 ± 1.7
AKI at admission, yes, n (%) 14 (35) 12 (30)
Mechanical ventilation at enrolment, yes, n (%) 25 (62) 23 (58)
Need for vasoactive drug, yes, n (%) 34 (85) 35 (87)
  1. NAC + DFX N-acetylcysteine plus deferoxamine, AKI acute kidney injury, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, SD standard deviation